Board of Directors

Arthur T. Sands, M.D., Ph.D.

Chief Executive Officer and Board Director

Arthur T. Sands, M.D., Ph.D. has served as the Chief Executive Officer at Nurix and a member of the company’s board of directors since September, 2014. In 2015, Dr. Sands and his management team completed a strategic collaboration with Celgene for the discovery, development and commercialization of novel small molecule therapeutics in oncology, inflammation and immunology that included an upfront payment of $150 million and significant milestones, royalties and options for commercialization of drugs. Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals and served as President, Chief Executive Officer and a Director from 1995 to 2014. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.

Tim Kutzkey, Ph.D.


Tim Kutzkey, Ph.D., is the Chairman of Nurix’s board of directors and also serves as the Interim President. He is a Partner at The Column Group and has contributed to the conception, formation and launch of several portfolio companies. He formerly was a scientist at KAI Pharmaceuticals, where his research focused on cell assay and pharmacodynamic marker development for selective protein kinase C inhibitors. Prior to KAI, Dr. Kutzkey studied at the University of California, Berkeley as a graduate student and postdoctoral scholar in the lab of Dr. Robert Tjian. He completed his Ph.D. on the biochemistry and genetics of long-range gene regulatory mechanisms. Dr. Kutzkey completed his undergraduate education at Stanford University.

David Lacey

Board Director

David Lacey joined Amgen in 1994 where, during the last five years of his tenure, he was the Head of Discovery Research, and managed more than 1200 employees. At any given time, Dr. Lacey oversaw over 100 actively-managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders and neuroscience. Scientifically, he played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen, which led to the development of the anti-RANKL human mAb denosumab, a blockbuster for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA) that had combined sales of $2 billion in 2015. Following his retirement in 2011, he has continued to be active in the biopharmaceutical industry. His current activities include advising academic institutions, biotechnology companies and venture capital firms. Dr. Lacey received both his undergraduate and medical degrees from the University of Colorado. Following the completion of his training, he served on the faculty at Washington University in St. Louis.

Jeff Tong, Ph.D.

Board Director

Jeff Tong is a Venture Partner with Third Rock Ventures where he focuses on drug discovery and development across the portfolio. He brings significant operational experience in building and growing early-stage biotechnology companies.

Prior to joining Third Rock, Jeff was Executive Chairman of the Board of Delinia, a company developing novel therapeutics for the treatment of autoimmune diseases. From 2010 to 2015, Jeff was the President and Chief Executive Officer of Nora Therapeutics. Prior to that, he was a member of the founding management team at Infinity Pharmaceuticals where he led its corporate as well as product development activities. Over the course of his career, Jeff has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through Phase 3 development, and developed integrated science/business strategies for building innovative biotechnology companies. Earlier in his career, Jeff worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research. Jeff received his educational training at the interface of molecular biology, organic chemistry and medicine and holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University.

Robert Tjian, Ph.D.

Board Director

Dr. Tjian joined The Column Group as a Discovery Partner in September 2016. Prior to that he served as President of the Howard Hughes Medical Institute from 2009-2016. Dr. Tjian discovered the first transcription factors, human proteins that bind to specific sections of DNA and play a critical role in regulating how genetic information is expressed into the thousands of biomolecules that keep cells, tissues and organisms alive. Dr. Tjian’s laboratory has focused on disruptions in the process of transcription that cause diseases such as cancer, metabolic syndromes and neuro-degenerative diseases. Dr. Tjian joined the University of California, Berkeley faculty in 1979, where he assumed several leadership roles, including Director of the Berkeley Stem Cell Center, Faculty Director of the Li Ka Shing Center for Biomedical and Health Sciences, and Head of the Siebel Stem Initiative. He currently serves as scientific advisor to the Chan Zuckerberg Initiative and the BioHub. Dr. Tjian is a member of the National Academy of Sciences and has received numerous awards including the Alfred P. Sloan Prize and the Louisa Gross Horwitz Prize.